Alzheimer's Disease Research Center

阿尔茨海默病研究中心

• 批准号: 10668229
• 负责人: SCOTT A SMALL
• 金额: $ 307.61万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10668229
• 关键词: Address; Advisory Committees; Alzheimer' s Disease; Alzheimer' s disease related dementia; Awareness; Biological; Biological Markers; Cell physiology; Cholesterol Homeostasis; Clinical; Clinical Investigator; Clinical Trials; Collaborations; Committee Members; Communities; Discipline; Disease; Early Diagnosis; Endosomes; Enrollment; Environment; Fostering; Genes; Genetic; Genomics; Goals; Immune response; Infrastructure; Institution; Intervention; Learning Module; Mission; Nerve Degeneration; Observational Study; Participant; Pathogenesis; Pathogenicity; Pathology; Pathway interactions; Patient Care; Patient Recruitments; Patients; Pharmaceutical Preparations; Prevention; Research; Research Infrastructure; Research Personnel; Resources; Therapeutic Trials; Time; Training; United States National Institutes of Health; Universities; Vision; Work; amyloid pathology; career; community organizations; data management; data submission; education research; interdisciplinary collaboration; interest; neuroimaging; neuroimmunology; neuropathology; outreach; patient outreach; phenomenological models; prevent; programs; recruit; success; synergism; tau Proteins; tool; trafficking; translational scientist

OVERALL PROJECT SUMMARY/ABSTRACT This is a new application for a P30 ADRC at Columbia University, continuing the tradition of our previous P50 ADRC that has existed at Columbia since 1989. Building off our prior accomplishments, the overall objective of the new ADRC is to support and promote cutting-edge research on Alzheimer’s disease (AD) and related disorders, both locally in our extensive campus and more globally with other institutions and national consortia. Subsumed within this objective the Center will have a more focused theme. The theme, focusing on ‘biological pathways’ implicated in AD pathogenesis, was decided on after internal deliberations, discussions with our External Advisory Committee members, and with NIH project officers. As reviewed throughout the proposal, we believe that this broad theme has many advantages. It will strengthen the overall objective by better serving our local community of basic, translational, and clinical investigators; and will generate new tools and resources that we will share with other institutions, consortia, and organizations. Additionally, the theme will allow each core to have both general aims that harmonize with other ADRCs and consortia, and theme-guided aims that emerge from our local strengths. As reviewed below, the theme will allow cores to synergize and work together in creating a research infrastructure that relate to the clinical phenomenology, neuropathology, neuroimaging, and genomics of AD. Since its inception 30 years ago, the ADRC at Columbia has established an elaborate infrastructure for research, fostered interdisciplinary collaborations, established a rich training environment, and promoted outreach and patient recruitment. At the same time the Center has become an active participant in a more global network comprised of other institutions, national consortia, and community organizations. During the many cycles of the P50 ADRC, the Center has attained most of its goals, as evidenced, for example, by the breadth of its scientific findings and by its high ranking of enrolled and active patients. In this proposal for a new P30 ADRC we will build off of these prior accomplishments moving forward, and will be motivated by two general goals. The first goal is to continue, as in previous cycles, to foster all research on AD and related disorders, while the second goal is to support the theme. We propose to achieve these goals through our well-integrated cores, which collectively establishes an infrastructure that generates a rich array of resources, biospecimens, and expertise. Besides the Administrative Core, these cores include a Clinical Core led by Dr. Lawrence Honig, a ‘Data Management and Statistical’ Core led by Dr. Howard Andrews, a Neuropathology Core led by Dr. Andrew Teich, a Biomarker Core led by Dr. Adam Brickman, a Genetics Core led by Dr. Christiane Reitz, a Neuroimmunology Core led by Dr. Phillip De Jager, an ‘Outreach, Retention, and Engagement’ Core led by Dr. William (Ted) Huey, and a ‘Research Education’ Module led by Dr. James Noble.

总体项目摘要/摘要 这是哥伦比亚大学P30 ADRC的新应用程序，延续了我们以前的传统 自1989年以来一直存在于哥伦比亚的P50 ADRC。建立我们先前的成就，总体目标 新的ADRC是支持和促进有关阿尔茨海默氏病（AD）及相关的尖端研究 在我们广泛的校园中，与其他机构和国家财团的全球范围内，疾病都在当地。 该目标包含在此目标中，中心将具有更为专注的主题。主题着眼于生物学 途径与AD发病机理有关，是在内部审议之后决定的，与我们的讨论 外部咨询委员会成员以及NIH项目官员。正如在整个提案中所审查的那样，我们 相信这个广泛的主题具有许多优势。它将通过更好地为我们的服务来增强整体目标 基本，翻译和临床研究人员的当地社区；并将生成新的工具和资源 我们将与其他机构，财团和组织分享。此外，主题将允许每个核心 具有与其他ADRC和财团协调的一般目标，以及主题引导的目标 从我们当地的优势。如下所述，该主题将允许核心协同和共同努力 创建与临床现象学，神经病理学，神经影像学和 AD的基因组学。 自30年前成立以来，哥伦比亚的ADRC已建立了一个精致的基础设施 研究，培养跨学科合作，建立了丰富的培训环境并促进 外展和患者招募。同时，该中心已成为更全球的活跃参与者 网络完成其他机构，国家财团和社区组织。在许多人期间 P50 ADRC的周期，该中心已经参加了大多数目标，例如 它的科学发现及其入学和活跃患者的高级排名。 在此新的P30 ADRC的建议中，我们将建立这些先前的成就，并 将受到两个一般目标的动机。第一个目标是像以前的周期一样继续进行所有研究 在广告和相关疾病上，第二个目标是支持主题。我们建议实现这些目标 通过我们良好的核心，共同建立了一个基础设施，产生了丰富的阵列 资源，生物测量和专业知识。除了行政核心，这些核心还包括临床核心 由劳伦斯·霍尼格（Lawrence Honig 由Andrew Teich博士领导的神经病理学核心，他是遗传学核心Adam Brickman博士的生物标志物核心 由克里斯蒂安·里兹（Christiane Reitz）博士领导，这是由菲利普·德·贾格（Phillip de Jager）博士领导的神经免疫学核心 William（Ted）Huey博士领导的订婚核心，以及由James Noble博士领导的“研究教育”模块。

项目成果

Focused ultrasound mitigates pathology and improves spatial memory in Alzheimer's mice and patients.

• DOI: 10.7150/thno.79898
• 发表时间: 2023
• 期刊: Theranostics
• 影响因子: 12.4
• 作者: Karakatsani ME;Ji R;Murillo MF;Kugelman T;Kwon N;Lao YH;Liu K;Pouliopoulos AN;Honig LS;Duff KE;Konofagou EE
• 通讯作者: Konofagou EE

Alzheimer-related altered white matter microstructural integrity in Down syndrome: A model for sporadic AD?

• DOI: 10.1002/dad2.12040
• 发表时间: 2020-01
• 期刊: Alzheimer's & dementia
• 作者: H. Rosas;E. Hsu;N. Mercaldo;F. Lai;M. Pulsifer;D. Keator;A. Brickman;J. Price;M. Yassa;C. Hom;S. Krinsky-McHale;W. Silverman;I. Lott;N. Schupf

Endosomal recycling reconciles the Alzheimer's disease paradox.

• DOI: 10.1126/scitranslmed.abb1717
• 发表时间: 2020-12-02
• 期刊: Science translational medicine
• 影响因子: 17.1
• 作者: Small SA;Petsko GA
• 通讯作者: Petsko GA

"ET Plus": Instability of the Diagnosis During Prospective Longitudinal Follow-up of Essential Tremor Cases.

• DOI: 10.3389/fneur.2021.782694
• 发表时间: 2021
• 期刊: Frontiers in neurology
• 影响因子: 3.4
• 作者: Iglesias-Hernandez D;Delgado N;McGurn M;Huey ED;Cosentino S;Louis ED
• 通讯作者: Louis ED

The (in)visible Brazilians: A perspective review on the need for brain health and dementia research with Brazilian immigrants in the United States.

• DOI: 10.1002/trc2.12425
• 发表时间: 2023-07
• 期刊: ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
• 影响因子: 4.8
• 作者: Simon, Sharon Sanz;Brucki, Sonia Maria Dozzi;Fonseca, Luciana Mascarenhas;Becker, Jacqueline;Cappi, Carolina;Marques, Andrea Horvath;Heyn, Patricia C;Goncalves, Priscila Dib;Martins, Silvia S;Busatto, Geraldo;Bertola, Laiss;Suemoto, Claudia Kimie;Nitrini, Ricardo;Caramelli, Paulo;Yassuda, Monica Sanches;Miotto, Eliane Correa;Grinberg, Lea Tenenholz;Arce Renteria, Miguel;Alegria, Margarita;Stern, Yaakov;Rivera-Mindt, Monica
• 通讯作者: Rivera-Mindt, Monica